Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cultured chondrocytes - Vericel

Drug Profile

Autologous cultured chondrocytes - Vericel

Alternative Names: Articel; Autologous cultured chondrocytes on porcine collagen membrane; MACI; MACI Implant; Matrix-applied-characterised-autologous-cultured-chondrocytes-Vericel; Matrix-induced autologous chondrocyte implant

Latest Information Update: 11 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verigen AG
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries
  • Phase II Osteonecrosis

Most Recent Events

  • 08 Mar 2024 Withdrawn for Knee injuries in Australia (Parenteral) (Vericel Corporation SEC filing, Form 10-K, March 2024)
  • 29 Feb 2024 Vericel Corporation plans a phase III trial for Cartilage defects in the ankle in 2025 (Vericel Corporation Pipeline, June 2024)
  • 29 Feb 2024 Vericel Corporation plans the commercial launch of MACI Arthroscopic in the third quarter of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top